WCLC 2025 - Posters & ePosters-P3.12.05 Patterns of EGFR Mutations and Real-World Experience of Therapeutic Interventions

P3.12.05 Patterns of EGFR Mutations and Real-World Experience of Therapeutic Interventions - a Community Oncology Study

Pdf Summary

This retrospective community oncology study from Western India analyzed EGFR mutation patterns, treatment approaches, and survival outcomes in 1,892 NSCLC patients diagnosed between March 2018 and September 2024. The median age was 64 years, with a small subset (n=21) under 40. EGFR mutations were identified in 28.2% (533/1892) of patients, aligning between reported prevalence ranges for India (10-15%) and East Asia (40-50%). Mutation prevalence varied by histology: adenocarcinoma (31.5%), adenosquamous (28.9%), squamous cell carcinoma (8.1%), and large cell carcinoma (12.5%). EGFR mutation rates were higher in females (36.4%) than males (22.7%).<br /><br />Among EGFR-mutated metastatic NSCLC patients (n=409), common mutations included exon 19 deletions and exon 21 L858R, with less frequent mutations such as G719X, L861Q, and S768I. Compound mutations and co-mutations (e.g., EGFR with TP53, ROS, ALK) were also noted. Regarding metastatic sites, bone and lymph nodes were prevalent.<br /><br />First-line treatment data for 365 patients showed 53.7% received first-/second-generation TKIs, 14.8% third-generation TKIs, and 18.3% combination TKI and chemotherapy. Median overall survival (mOS) was 33 months overall; 30.1 months with 1st/2nd-generation TKIs and 35.3 months with 3rd-generation TKIs. Patients on chemotherapy alone had not reached median OS at follow-up (median 29.7 months).<br /><br />The study highlights the need for improved accessibility to next-generation sequencing and optimized use of advanced TKIs, alone or combined with chemotherapy, to enhance survival in resource-limited settings. These real-world findings contribute important prevalence and treatment outcome data for EGFR-mutated NSCLC in community oncology practice in Western India.

Asset Subtitle

Kunal Jobanputra

Meta Tag

Speaker Kunal Jobanputra

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR mutation

NSCLC

Western India

adenocarcinoma

tyrosine kinase inhibitors

exon 19 deletion

exon 21 L858R

overall survival

next-generation sequencing

community oncology